| |
| | SCIENCE POLICY: ON THE US FOOD AND DRUG ADMINISTRATION |
 | | In important progress that is largely attributable to the Food and Drug Administration Modernization Act, the agency has adopted a more streamlined approach to clinical development -- for example, through the use of surrogate markers for accelerated approval or approval on the basis of a single multicenter clinical trial. |
 | | 3) The drug review process has been described as structurally similar to many decisions made by other regulatory agencies, such that it is characterized by high uncertainty, avoidance of observable error, and low (reputational) reversibility, with drug recalls harming the reputation of the FDA for a faulty approval decision,[5] and often severely affecting the manufacturer. |
 | | The drug industry manufactures, distributes, and publicizes powerful chemical and biologic agents that have proven benefits and that physicians sometimes fail to use as often as they should, or in sufficient doses.(1) In this sense, industry's efforts to encourage the use of some agents by physicians can be seen as contributing to the public health. |
| scienceweek.com /2005/sc050225-4.htm (1863 words) |
|